Keyphrases
Esophagogastric Adenocarcinoma
100%
Randomized Phase II Trial
100%
Phase II Trial
100%
Capecitabine
100%
Carboplatin
100%
Oxaliplatin
100%
Epirubicin
100%
Docetaxel
100%
5-fluorouracil (5-FU)
30%
1-year Survival
20%
Cisplatin
20%
Febrile Neutropenia
20%
Overall Survival
10%
First-line Regimen
10%
June 2014
10%
Treatment-related Adverse Events
10%
Intolerance
10%
HER2-positive
10%
Progression-free Survival
10%
Chemotherapy Regimen
10%
Previously Treated
10%
First-line Chemotherapy
10%
Pharmacology, Toxicology and Pharmaceutical Science
Oxaliplatin
100%
Docetaxel
100%
Carboplatin
100%
Capecitabine
100%
Epirubicin
100%
Adenocarcinoma
100%
Fluorouracil
20%
Febrile Neutropenia
20%
Cisplatin
20%
Progression Free Survival
10%
First-Line Chemotherapy
10%
Chemotherapy Regimens
10%
Survival Rate
10%
Overall Survival
10%
Adverse Event
10%